Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Multiple lines of evidence demonstrate that elevated levels of atherogenic lipoproteins are a major risk factor for atherosclerotic cardiovascular disease (ASCVD) and their reduction is a cornerstone of ASCVD prevention.1-4 A log-linear relationship between absolute low-density lipoprotein cholesterol (LDL-C) and ASCVD risk is supported by genomic and cohort studies, and randomized clinical trials.1 A meta-analysis of 21 clinical trials of LDL-C –lowering drugs indicated that each 1-mmol/L LDL-C lowering was associated with a relative reduction in risk of major vascular events of 23% after 5 years, with increasing benefit observed with greater duration of treatment.

Source: Journal of Clinical Lipidology - June 3, 2023 Category: Lipidology Authors: Christie M. Ballantyne, Marc Ditmarsch, John JP Kastelein, Adam J. Nelson, Douglas Kling, Andrew Hsieh, Danielle L. Curcio, Kevin C. Maki, Michael H. Davidson, Stephen J. Nicholls Tags: Original Research Source Type: research